Arecor Therapeutics has said it expects to receive top-line date later this year from the phase 1 trial currently underway for AT247, its ultra-rapid insulin injection.
Sarah Howell, Arecor chief executive, said the results would be key to further demonstrating AT247's superiority against current gold standard treatments and its potential to facilitate a fully closed loop artificial pancreas.
“This could provide a significant inflexion point for the group. In H2, we also expect to initiate a further clinical trial for AT278 in people living with Type 2 diabetes," she said in a statement.
Arecor recently acquired Tetris Pharma, which Howell said was a revenue-generating sales, marketing and distribution platform that complements its existing specialty hospitals products franchise.
Tetris lead product, Ogluo, meets a key patient need for people living with diabetes at risk of severe hypoglycaemia, which is a therapeutic area Arecor knows well, she added.
The comments came as Arecor reported that its revenues in the six months to end-June 2022 were £0.7mln with net losses of £4.4mln (H1 2022: £3.1mln). Arecor had cash and equivalents of £13.7mln at the end of the first half.